142 related articles for article (PubMed ID: 8073307)
21. Prednisone, oral etoposide, and novantrone for treatment of non-Hodgkin's lymphoma: a preliminary report.
Goss PE; Burkes R; Rudinskas L; King M; Chow W; Myers R; Davidson M; Poldre P; Crump M; Sutton D
Semin Hematol; 1994 Apr; 31(2 Suppl 3):23-9. PubMed ID: 8073303
[No Abstract] [Full Text] [Related]
22. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.
Hiddemann W; Unterhalt M; Herrmann R; Wöltjen HH; Kreuser ED; Trümper L; Reuss-Borst M; Terhardt-Kasten E; Busch M; Neubauer A; Kaiser U; Hanrath RD; Middeke H; Helm G; Freund M; Stein H; Tiemann M; Parwaresch R
J Clin Oncol; 1998 May; 16(5):1922-30. PubMed ID: 9586911
[TBL] [Abstract][Full Text] [Related]
23. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
[TBL] [Abstract][Full Text] [Related]
25. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization.
Arranz R; García-Alfonso P; Sobrino P; Zamora P; Carrión R; García-Laraña J; Pérez G; López J; Lavilla E; Lozano M; Rayón C; Colomer R; Barón MG; Flores E; Pérez-Manga G; Fernández-Rañada JM
J Clin Oncol; 1998 Apr; 16(4):1538-46. PubMed ID: 9580385
[TBL] [Abstract][Full Text] [Related]
26. Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: five-year follow-up.
Andersen JW; Smalley RV
N Engl J Med; 1993 Dec; 329(24):1821-2. PubMed ID: 8232506
[No Abstract] [Full Text] [Related]
27. The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
Chisesi T
Leuk Lymphoma; 1993 Jan; 9(1-2):63-9. PubMed ID: 8477203
[TBL] [Abstract][Full Text] [Related]
28. [A comparative trial of C-novantrone OP(CNOP) vs C-adriamycin OP(CHOP) in the treatment of stage II-IV malignant lymphoma--the preliminary report].
Chuang MW; Tzeng CH; Chiou TJ; Chiu CF; Hsieh RK; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 1988 Jan; 41(1):51-6. PubMed ID: 3167650
[No Abstract] [Full Text] [Related]
29. Cyclophosphamide, mitoxantrone, vincristine and prednisone in the treatment of non-Hodgkin's lymphoma.
Vorobiof DA; Terblanche AP; Falkson CI; Falkson G
Oncology; 1988; 45(5):378-9. PubMed ID: 3412747
[TBL] [Abstract][Full Text] [Related]
30. [The use of novantrone in combination with other preparations in hematosarcoma patients].
Kruglova GV; Demina EA; Evtushenko VV
Ter Arkh; 1992; 64(7):40-3. PubMed ID: 1440366
[No Abstract] [Full Text] [Related]
31. The treatment of non-Hodgkin's lymphoma with mitoxantrone-containing regimens.
Sonneveld P
Semin Oncol; 1995 Feb; 22(1 Suppl 1):29-31. PubMed ID: 7863349
[No Abstract] [Full Text] [Related]
32. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Lyman GH; Delgado DJ
Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
[TBL] [Abstract][Full Text] [Related]
33. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
[TBL] [Abstract][Full Text] [Related]
34. A comparative study of CHOP versus MEVP (mitoxantrone, etoposide, vindesine, prednisolone) therapy for intermediate-grade and high-grade non-Hodgkin's lymphoma: a prospective randomized study.
Takagi T; Sampi K; Sawada U; Sakai C; Oguro M
Int J Hematol; 1993 Jan; 57(1):67-71. PubMed ID: 8477064
[TBL] [Abstract][Full Text] [Related]
35. [Comparison of effectiveness of adriamycin and epirubicin administered in the CHOP protocol to patients with malignant non-hodgkin's lymphoma].
Rolski J; Koralewski P; Pawlicki M
Wiad Lek; 1993 May; 46(9-10):356-9. PubMed ID: 8236992
[TBL] [Abstract][Full Text] [Related]
36. Treatment of intermediate-grade and high-grade non-Hodgkin's lymphoma.
Machida U; Kami M; Hirai H
N Engl J Med; 1998 Nov; 339(20):1475-6; author reply 1477. PubMed ID: 9841318
[No Abstract] [Full Text] [Related]
37. Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non-Hodgkin's lymphoma.
Yau JC; Germond C; Gluck S; Cripps C; Verma S; Burns BF; Koski TM; Lister DC; Goss GD
Am J Hematol; 1998 Oct; 59(2):156-60. PubMed ID: 9766801
[TBL] [Abstract][Full Text] [Related]
38. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
[TBL] [Abstract][Full Text] [Related]
39. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
[TBL] [Abstract][Full Text] [Related]
40. Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype.
Marotta G; Bigazzi C; Bocchia M; Forconi F; Lauria F
Haematologica; 1998 Sep; 83(9):853-4. PubMed ID: 9825583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
